Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2004 2
2005 6
2006 1
2007 2
2008 2
2009 3
2010 7
2011 5
2012 3
2013 6
2014 6
2015 8
2016 3
2017 4
2018 5
2019 7
2020 13
2021 10
2022 10
2023 10
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

103 results

Results by year

Filters applied: . Clear all
Page 1
Is oligoprogression a potentially curable disease in epidermal growth factor receptor mutant lung adenocarcinoma?
Chekhun S, Lopez-Paradís A, Urbizu A, Morán T, Mañes A, Cucurull M, Martínez-Barenys C, Teruel I, Moragas G, Carcereny E, Muñoz Mármol AM, Saigí M. Chekhun S, et al. Among authors: moran t. Explor Target Antitumor Ther. 2023;4(6):1182-1187. doi: 10.37349/etat.2023.00191. Epub 2023 Dec 13. Explor Target Antitumor Ther. 2023. PMID: 38213544 Free PMC article.
Olaparib maintenance versus placebo in platinum-sensitive non-small cell lung cancer: the Phase 2 randomized PIPSeN trial.
Postel-Vinay S, Coves J, Texier M, Aldea M, Gazzah A, Dómine M, Planchard D, De Las Peñas R, Sala Gonzalez MA, Viteri S, Perez J, Ortega AL, Moran T, Camps C, Lopez-Martin A, Provencio M, Soria JC, Besse B, Massuti B, Rosell R. Postel-Vinay S, et al. Among authors: moran t. Br J Cancer. 2024 Feb;130(3):417-424. doi: 10.1038/s41416-023-02514-5. Epub 2023 Dec 14. Br J Cancer. 2024. PMID: 38097741 Clinical Trial.
Characterization of a cohort of metastatic lung cancer patients harboring KRAS mutations treated with immunotherapy: differences according to KRAS G12C vs. non-G12C.
Notario L, Cucurull M, Cerdà G, Sanz C, Carcereny E, Muñoz-Mármol A, Hernández A, Domènech M, Morán T, Sánchez-Céspedes M, Costa M, Mate JL, Esteve A, Saigí M. Notario L, et al. Among authors: moran t. Front Oncol. 2023 Oct 17;13:1239000. doi: 10.3389/fonc.2023.1239000. eCollection 2023. Front Oncol. 2023. PMID: 37916173 Free PMC article.
Correction to: SEOM-GECP Clinical guidelines for diagnosis, treatment and follow-up of small-cell lung cancer (SCLC) (2022).
García-Campelo R, Sullivan I, Arriola E, Insa A, Juan Vidal O, Cruz-Castellanos P, Morán T, Reguart N, Zugazagoitia J, Dómine M. García-Campelo R, et al. Among authors: moran t. Clin Transl Oncol. 2023 Sep;25(9):2760-2762. doi: 10.1007/s12094-023-03290-7. Clin Transl Oncol. 2023. PMID: 37556098 Free PMC article. No abstract available.
Perioperative Nivolumab and Chemotherapy in Stage III Non-Small-Cell Lung Cancer.
Provencio M, Nadal E, González-Larriba JL, Martínez-Martí A, Bernabé R, Bosch-Barrera J, Casal-Rubio J, Calvo V, Insa A, Ponce S, Reguart N, de Castro J, Mosquera J, Cobo M, Aguilar A, López Vivanco G, Camps C, López-Castro R, Morán T, Barneto I, Rodríguez-Abreu D, Serna-Blasco R, Benítez R, Aguado de la Rosa C, Palmero R, Hernando-Trancho F, Martín-López J, Cruz-Bermúdez A, Massuti B, Romero A. Provencio M, et al. Among authors: moran t. N Engl J Med. 2023 Aug 10;389(6):504-513. doi: 10.1056/NEJMoa2215530. Epub 2023 Jun 28. N Engl J Med. 2023. PMID: 37379158 Clinical Trial.
Author Correction: BIM and mTOR expression levels predict outcome to erlotinib in EGFR-mutant non-small-cell lung cancer.
Karachaliou N, Codony-Servat J, Teixidó C, Pilotto S, Drozdowskyj A, Codony-Servat C, Giménez-Capitán A, Molina-Vila MA, Bertrán-Alamillo J, Gervais R, Massuti B, Morán T, Majem M, Felip E, Carcereny E, García-Campelo R, Viteri S, González-Cao M, Morales-Espinosa D, Verlicchi A, Crisetti E, Chaib I, Santarpia M, Luis Ramírez J, Bosch-Barrera J, Felipe Cardona A, de Marinis F, López-Vivanco G, Miguel Sánchez J, Vergnenegre A, Sánchez Hernández JJ, Sperduti I, Bria E, Rosell R. Karachaliou N, et al. Among authors: moran t. Sci Rep. 2023 Mar 3;13(1):3620. doi: 10.1038/s41598-023-30374-9. Sci Rep. 2023. PMID: 36869103 Free PMC article. No abstract available.
Dynamic changes in circulating tumor DNA assessed by shallow whole-genome sequencing associate with clinical efficacy of checkpoint inhibitors in NSCLC.
Carbonell C, Frigola J, Pardo N, Callejo A, Iranzo P, Valdivia A, Priano I, Cedrés S, Martinez-Marti A, Navarro A, Lenza L, Soleda M, Gonzalo-Ruiz J, Vivancos A, Sansó M, Carcereny E, Morán T, Amat R, Felip E. Carbonell C, et al. Among authors: moran t. Mol Oncol. 2023 May;17(5):779-791. doi: 10.1002/1878-0261.13409. Epub 2023 Mar 21. Mol Oncol. 2023. PMID: 36852704 Free PMC article.
103 results